New biologics for Crohn's: do they work? study reveals clues
NCT ID NCT04923100
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed study from China looked at 50 adults with Crohn's disease who were treated with two newer biologic drugs, Ustekinumab and Vedolizumab. The goal was to see how well these drugs control the disease and what factors might predict a good response. By analyzing past medical records, researchers hope to find clues that help doctors choose the right treatment for each patient.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Ustekinumab and Vedolizumab
What this could lead to
If successful, this could help doctors better predict which Crohn's patients will benefit most from these newer biologics.
What could go wrong
This is a small, observational study (50 people) that looks back at past data, so it cannot prove cause and effect. Results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CROHN DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
the Sixth Affiliated Hospital of Sun Yat-Sen University
Guangzhou, Guangdong, 501655, China